Mirae Asset Global Investments Co., Ltd. Anavex Life Sciences Corp. Transaction History

Mirae Asset Global Investments Co., Ltd.

  • $22.5 Billion
  • Q3 2024

A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 3,067 shares of AVXL stock, worth $23,431. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,067
Previous 2,527 21.37%
Holding current value
$23,431
Previous $10,000 70.0%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024
BUY
$4.11 - $7.04 $2,219 - $3,801
540 Added 21.37%
3,067 $17,000
Q2 2024

Jul 30, 2024
SELL
$3.39 - $5.02 $177,374 - $262,661
-52,323 Reduced 95.39%
2,527 $10,000
Q1 2024

May 01, 2024
BUY
$4.55 - $6.75 $57,912 - $85,914
12,728 Added 30.22%
54,850 $279,000
Q4 2023

Jan 24, 2024
SELL
$5.04 - $9.95 $3,442 - $6,795
-683 Reduced 1.6%
42,122 $392,000
Q3 2023

Oct 26, 2023
SELL
$6.55 - $9.37 $20,874 - $29,862
-3,187 Reduced 6.93%
42,805 $280,000
Q2 2023

Aug 10, 2023
SELL
$7.66 - $9.5 $43,907 - $54,454
-5,732 Reduced 11.08%
45,992 $373,000
Q1 2023

May 04, 2023
BUY
$8.32 - $11.75 $146,257 - $206,553
17,579 Added 51.48%
51,724 $443,000
Q4 2022

Feb 09, 2023
BUY
$7.65 - $14.43 $34,478 - $65,036
4,507 Added 15.21%
34,145 $316,000
Q3 2022

Nov 10, 2022
BUY
$8.9 - $12.86 $76,904 - $111,123
8,641 Added 41.15%
29,638 $306,000
Q2 2022

Jul 26, 2022
BUY
$7.31 - $12.84 $153,488 - $269,601
20,997 New
20,997 $210,000

Others Institutions Holding AVXL

# of Institutions
156
Shares Held
26.5M
Call Options Held
673K
Put Options Held
811K
View Full List

About ANAVEX LIFE SCIENCES CORP.

AVXL Quotes by TradingView
  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $595M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Mirae Asset Global Investments Co., Ltd. Portfolio

Follow Mirae Asset Global Investments Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email